Advice
References
References
Castelnuovo E, Thompson‑Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K (2006) The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technology Assessment 10(32)
Cha YJ, Park Q, Lang ES, Yoo BC, Park KU, Kim JW, Hwang YS, Kim MH (2013) Performance evaluation of the OraQuick Hepatitis C virus Rapid Antibody Test. Annals of Laboratory Medicine 33: 184–9
Curtis L (2013) PSSRU 2013 [online; accessed 18 November 2014]
Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E (2011) Public health implications of rapid hepatitis C screening with an oral swab for community-based organisations serving high-risk populations. American Journal of Public Health 101(11): 2151–5
Gao F, Talbot EA, Loring CH, Power JJ, Dione‑Odom J, Alroy‑Preis S, Jackson P, Bean CL (2014) Performance of the OraQuick HCV Rapid Antibody Test for screening exposed patients in a hepatitis C outbreak investigation. Journal of Clinical Microbiology 52(7): 2650–2
Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, Page K (2014) Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health 14(645): 1471–2458
Hepatitis C Trust (2014) About hepatitis C [online; accessed 12 November 2014]
Larrat S, Bourdon C, Baccard M, Garnaud C, Mathieu S, Quesada JL, Signori‑Schmuck A, Germi R, Blanc M, Leclercq P, Hilleret MN, Leroy V, Zarski JP, Morand P (2012) Performance of an antigen-antibody combined assay for hepatitis C virus testing without venepuncture. Journal of Clinical Virology 55: 220–5
Lee SR, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Friel T, Berne CA, Kardos KW (2010) Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. Journal of Clinical Virology 48: 15–7
Lee Sr, Kardos KW, Schiff E, Berne CA, Mounzwer K, Banks AT, Tatum HA, Friel TJ, DeMicco MP, Lee WM, Eder S, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst JL, Kriebel L, Feiss G, Roehler M (2011) Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. Journal of Virological Methods 172: 27–31
Lee SR, Roehler M, Schiff E, Delgado‑Borrego A, Friel T, La Marca A, Dickson R, Sulkowski M, Borders J, Allen G, Kurtz L, Kardo K, Gregg R (2012) Use of rapid testing to prospectively identify HCV co-infection in populations with high HIV prevalence. Presented by Lee SR at XIX International AIDS Conference, 22–27 July, Washington DC, USA. [Conference abstract]
Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL (2014) Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. Journal of Community Health 29: 922–34
NHS Choices (October 2013) Hepatitis C [online; accessed 11 November 2014]
O'Connell RJ, Gates RG, Bautista CT, Imbach M, Eggleston JC, Beardsley SG, Manak MM, Gonzales R, Rentas FJ, Macdonald VW, Cardo LJ, Reiber DT, Stramer SL, Michael NL, Peel SA (2013) Laboratory evaluation of rapid test kits to detect hepatitis C antibody for use in predonation screening and emergency settings. Transfusion 53(3): 505–17
Public Health England (July 2014) Hepatitis C in the UK [online; accessed 11 November 2014]
Public Health England (November 2014) Shooting up: infections among people who inject drugs in the UK, update November 2014 [online; accessed 30 January 2015]
Scalioni LDP, Cruz HM, de Paula VS, Miguel JC Marques VA, Villela‑Nogueira CA, Milagres FAP, Cruz MS, Bastos FI, Andrade TM, Motta‑Castro ARC, Lewis‑Ximenes LL, Lampe E, Villar LM (2014) Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations. Journal of Clinical Virology 60: 200–5
Stockman LJ, Guilfoyle SM, Benoit AL, Vergeront JM, Davis JP (2014) Rapid hepatitis C testing among persons at increased risk for infection – Wisconsin, 2012–2013. CDC Morbidity and Mortality Weekly Report 63(14): 309–11
Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators (2006) Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technology Assessment 10(21): 1–113, iii